Mohammad Daaif, MD
Neurology · Aurora, ILNPI 1720271331
Payments from drug & device makers
Across 52 payments — averaging $17.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$159
- Bristol Myers Squibb$149
- Supernus Pharmaceuticals, Inc.$100
- Adamas Pharmaceuticals, Inc.$70
- AbbVie$56
- Livanova USA, Inc.$38
- plus $325 from 17 others
What the payments were for
- Speaking & faculty fees$202%
- Food & beverage$87898%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 9 | $159 |
| Bristol Myers Squibb | 9 | $149 |
| Supernus Pharmaceuticals, Inc. | 5 | $100 |
| Adamas Pharmaceuticals, Inc. | 4 | $70 |
| AbbVie(2 entities) | 3 | $56 |
| Livanova USA, Inc. | 2 | $38 |
| Biogen | 2 | $33 |
| Novartis | 2 | $30 |
| Portola Pharmaceuticals, LLC | 1 | $26 |
| EMD Serono, Inc. | 2 | $23 |
| UCB, Inc. | 1 | $23 |
| Abbott | 1 | $20 |
| Acorda Therapeutics, Inc | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
| Greenwich Biosciences, Inc. | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Boston Scientific | 1 | $15 |
| AstraZeneca | 1 | $14 |
| Genentech USA, Inc. | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| MDD US Operations, LLC | 1 | $11 |
How this compares
$898 in reported general payments places this provider in the 50th percentile of 790 neurology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 65 | $1,321 |
| Gabapentin | 47 | $741 |
| Carbamazepine | 11 | $720 |
| Pregabalin | 11 | $576 |
| Donepezil Hcl | 61 | $493 |
| Topiramate | 14 | $339 |
| Divalproex Sodium ErDivalproex Sodium | 11 | $242 |
| Memantine Hcl | 16 | $137 |
| RizatriptanRizatriptan Benzoate | 12 | $118 |
| Nortriptyline Hcl | 13 | $77 |
| Tizanidine Hcl | 14 | $67 |
Paid to pharmacies, not to this prescriber.
Other neurology in Aurora
- Daniel WynnNorthbrook$13.9M
- Concetta ForchettiElk Grove Village$8.5M
- Tatyana SimuniChicago$3.5M
- Danny BegaChicago$2.8M
- Thomas AlaSpringfield$2.4M
- Augusto MiravalleChicago$2.1M
- Leonard Verhagen MetmanChicago$1.8M
- Anthony RederBurr Ridge$1.6M
- Dusan StefoskiChicago$1.5M
- Kourosh RezaniaChicago$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.